NCT03671811View on ClinicalTrials.gov

Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

January 21, 2019

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions
Atypical Endometrial HyperplasiaEndometrial Carcinoma
Interventions
DRUG

Megestrol Acetate

Given PO

BIOLOGICAL

Pterostilbene

Given PO

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT03671811 - Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | Biotech Hunter | Biotech Hunter